Top

World Journal of Urology

Published in:

Open Access 01-06-2008 | Topic Paper

Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer

Authors: I. M. van Oort, J. A. Witjes, D. E. G. Kok, L. A. L. M. Kiemeney, C. A. Hulsbergen-vandeKaa

Published in: World Journal of Urology | Issue 3/2008

Abstract

Objectives

Previous studies suggest that maximum tumor diameter (MTD) is a predictor of recurrence in prostate cancer (PC). This study investigates the prognostic value of MTD for biochemical recurrence (BCR) in patients with PC, after radical prostatectomy (RP), with emphasis on high-risk localized prostate cancer.

Methods

RP specimens of 542 patients were evaluated with a median follow-up of 39.5 months (range 0.6–150 months). MTD was defined as the largest diameter of the largest tumor; high-risk as ≥T2c or PSA level > 20 ng/ml or Gleason score ≥8 and BCR as two consecutive PSA levels > 0.10 ng/ml. Proportional hazards multivariable regression models were composed to determine prognostic factors for BCR.

Results

Overall, 114 patients developed BCR after RP. The overall 5-year risk of BCR was 25% (95% CI = 20.4–29.6), and median MTD was 24 mm (range 1–65). MTD in the total and high-risk group was associated with total tumor volume, volume of the largest tumor, pre-operative PSA levels, and Gleason score. In a univariable analyses, MTD was weakly associated with risk of BCR (HR = 1.02 per mm increase, 95% CI = 1.002–1.035, P = 0.024) in the total group; in the high-risk group this association was lost (HR = 1.01, 95%CI = 0.99–1.03, P = 0.18). Multivariable analyses indicated that positive surgical margins, higher Gleason score, advanced pathological stage, and multiple tumors were the main prognostic factors for BCR irrespective of the risk profile. MTD did not provide additional information.

Conclusions

MTD is not an independent prognostic factor for BCR in patients treated with RP, irrespective of the risk profile.

Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555–565PubMedCrossRef

D’Amico AV, Whittington R, Malkowicz SB et al (2002) Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95:281–286PubMedCrossRef

Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D’Amico AV (1998) The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 83:748–752PubMedCrossRef

Epstein JI, Carmichael M, Partin AW, Walsh PC (1993) Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 149:1478–1481PubMed

Salomon L, Levrel O, Anastasiadis AG et al (2003) Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 43:39–44PubMedCrossRef

Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM (1999) Biological determinants of cancer progression in men with prostate cancer. JAMA: 281:1395–1400PubMedCrossRef

Bostwick DG, Graham SD Jr, Napalkov P et al (1993) Staging of early prostate cancer: a proposed tumor volume-based prognostic index. Urology 41:403–411PubMedCrossRef

Nelson BA, Shappell SB, Chang SS et al (2006) Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 97:1169–1172PubMedCrossRef

Wise AM, Stamey TA, McNeal JE, Clayton JL (2002) Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60:264–269PubMedCrossRef

10.

Humphrey PA, Vollmer RT (1997) Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 10:326–333PubMed

11.

Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D’Amico AV (1999) Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens. Validation in a cohort of 434 patients. Am J Clin Pathol 111:641–644PubMed

12.

Eichelberger LE, Koch MO, Daggy JK, Ulbright TM, Eble JN, Cheng L (2003) Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am J Clin Pathol 120:386–391PubMedCrossRef

13.

Ruijter ET, Miller GJ, Aalders TW et al (1997) Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. J Pathol 183:369–375PubMedCrossRef

14.

Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer, New York

15.

Dvorak T, Chen MH, Renshaw AA, Loffredo M, Richie JP, D’Amico AV (2005) Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer. Urology 66:1024–1028PubMedCrossRef

16.

Eichelberger LE, Koch MO, Eble JN, Ulbright TM, Juliar BE, Cheng L (2005) Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol 18:886–890PubMedCrossRef

17.

Qian J, Wollan P, Bostwick DG (1997) The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol: 28:143–148PubMedCrossRef

Title: Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer
Authors: I. M. van Oort
J. A. Witjes
D. E. G. Kok
L. A. L. M. Kiemeney
C. A. Hulsbergen-vandeKaa
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 3/2008
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-008-0242-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2008

High-risk prostate cancer in the United States, 1990–2007

Radical prostatectomy for high-risk prostate cancer

Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability

Substratification of high-risk localised prostate cancer treated by radical prostatectomy

Initial clinical experience with full-length metal ureteral stents for obstructive ureteral stenosis

Curcumin protects against ischemia/reperfusion injury in rat kidneys